Table 1. Patients' characteristics at presentation.
| Patient characteristics | All (N=269) | DAdS (N=133) | DAiS (N=136) | P-value* |
|---|---|---|---|---|
| Age: median (IQR), year | 76 (10) | 76 (11) | 75.5 (10.5) | 0.22 |
| Initial PSA: | ||||
| Median (IQR), ng ml−1 | 79.2 (179) | 76.7 (176) | 81.1 (193.7) | 0.34 |
| Pre-study androgen deprivation: median (IQR), month | ||||
| Non-metastatic | 59 (49) | 78 (38) | 41 (40) | 0.02 |
| Metastatic | 29 (39) | 34 (54) | 27 (29) | 0.29 |
| No./total (%) | No./total (%) | No./total (%) | ||
| Metastatic disease | 204/269 (76) | 102/133 (77) | 102/136 (75) | 0.77 |
| Gleason | 0.72 | |||
| ⩽6 | 44/216 (20.4) | 23/112 (20.5) | 21/104 (20.2) | |
| 7 | 55/216 (25.4) | 26/112 (23.2) | 29/104 (27.9) | |
| 8–10 | 117/216 (54.2) | 63/112 (56.3) | 54/104 (51.9) | |
| Initial therapy | 0.86 | |||
| GNRH | 188/259 (72.6) | 92/130 (70.8) | 96/129 (74.4) | |
| MAB | 19/259 (7.3) | 11/130 (8.4) | 8/129 (6.2) | |
| AA | 13/259 (5.0) | 8/130 (6.2) | 5/129 (3.9) | |
| Surgery | 21/259 (8.1) | 10/130 (7.7) | 11/129 (8.5) | |
| RT | 18/259 (7.0) | 9/130 (6.9) | 9/129 (7.0) | |
| Raised (⩾130 IU l−1) alkaline phosphatase | 83/212 (39.2) | 39/103 (37.9) | 44/109 (40.4) | 0.71 |
| Haemoglobin (⩾11 g dl−1) | 273/269 (88.1) | 117/133 (88.0) | 120/136 (88.2) | 0.95 |
| Performance status | 1.00 | |||
| 0 | 95/269 (35.3) | 47/133 (35.3) | 48/136 (35.3) | |
| 1–3 | 174/269 (64.7) | 86/133 (64.7) | 88/136 (64.7) | |
| Positive bone scan | 204/269 (75.8) | 102/133 (76.7) | 102/136 (75) | 0.75 |
| PSA normalised | 167/269 (62.1) | 82/133 (61.7) | 85/136 (62.5) | 0.89 |
| Previous chronic disease | ||||
| Myocardial infarction | 12/194 (6.2) | 8/101 (8) | 4/93 (4.3) | 0.38 |
| Diabetes mellitus | 10/194 (5.2) | 3/101 (3) | 7/93 (7.5) | 0.20 |
| Respiratory | 23/194 (11.9) | 15/101 (14.9) | 8/93 (8.6) | 0.18 |
Abbreviations: AA=anti-androgen; DAiS=Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol; DAdS=Dexamethasone, Aspirin, and deferred (until disease progression) Diethylstilbestrol; GnRH=gonadorelin analogue; IQR=inter-quartile range; MAB=maximum androgen blockade; PSA=prostate-specific antigen; RT=radiotherapy.
*P-values refer to differences between patients receiving DAdS and DAiS.